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Abstract
The sequencing of the head and neck cancer has provided a blueprint of the most frequent genetic alterations in this
cancer type. They include inactivating mutations in Notch, p53, and p16ink4a tumor suppressor genes, in addition to
nonoverlapping activating mutations of the PIK3CA and RAS oncogenes or inactivation of the tumor suppressor gene
PTEN. Notably, these genetic alterations, alongwith epigenetic changes, result in increased activity of phosphoinositide
3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is present in most head and neck
squamous cell carcinomas (HNSCCs). Moreover, we show here that approximately 30% of HNSCCs exhibit reduced
PTEN expression. We challenged the biologic relevance of this finding by combining the intraoral administration of a
tobacco surrogate, 4-nitroquinoline 1-oxide, with a genetically defined animal model displaying reduced PTEN expres-
sion, achieved by the conditional deletion ofPtenusing the keratin promoter 14CRE-lox system. This provided a specific
genetic and environmentally defined animal model for HNSCC that resulted in the rapid development of oral-specific
carcinomas. Under these experimental conditions, control mice did not develop HNSCC lesions. In contrast, mostmice
harboringPtendeficiency developedmultiple SCC lesions in the lateral border and ventral part of the tongue and floor of
the mouth, which are the preferred anatomic sites for human HNSCC. Overall, our study highlights the likely clinical
relevance of reduced PTEN expression and/or inactivation in HNSCC progression, while the combined Pten deletion
with exposure to tobacco carcinogens or their surrogates may provide a unique experimental model system to study
novel molecular targeted treatments for HNSCC patients.
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Introduction
Head and neck squamous cell carcinomas (HNSCCs) represent one
of the 10 most common cancers worldwide [1]. Tobacco and alcohol
consumption are well-known risk factors for this cancer type, along
with the recently described involvement of human papillomavirus
infection [1–3]. Although very rarely diagnosed in the early stages,
the survival rate for early diagnosed HNSCC patients is approximately
82.4% within the first 5 years, whereas for late-stage HNSCC the
survival rate drops to 34.9% according to the National Cancer
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Institute Surveillance Epidemiology and End Results (www.seer.
cancer.gov). An additional factor influencing survival is the develop-
ment of multiple primary tumors that are also associated to field
cancerization and chronic tobacco exposure, constituting the most
common cause of treatment failure and death among early-stage
patients [1,2,4].
Although some of the genetic and epigenetic events underlying
this complex disease have been identified [5,6], the molecular path-
ways involved in HNSCC tumor development and progression are
still poorly understood. Recently, the genome-wide sequence analyses
of HNSCC have enlightened the field by defining its most frequent
somatic genetic alterations [5,6]. Interestingly, a large number of muta-
tions were identified, which include the known TP53 and HRAS
mutations and other previously unrecognized ones, such as mutations
in the NOTCH family genes (NOTCH1, NOTCH2, and NOTCH3).
These multiple mutations confirmed the heterogeneity of the HNSSC
tumors, which is reflected in the diverse biology, response to treatment,
and prognosis of HNSCC patients. Additionally, several mutations
were identified in the phosphoinositide 3-kinase (PI3K)/mammalian
target of rapamycin (mTOR) pathway, including PIK3CA (8–10%),
TSC1/2 (5–8%), and PTEN (5–10%) [5–8], all of which result in
PI3K/AKT/mTOR pathway activation. Detailed exon sequencing in
one study revealed PTEN mutations in up to 23% of the tumor sam-
ples [7]. In particular, loss of chromosome 10 and missense mutations
were identified in PTEN exons 5, 6, 7, and 8 [7]. Furthermore, muta-
tions present in the same pathway are rarely reported in the same tumor
[6,9,10], which underscores the importance of these pathways in the
pathophysiology of this disease. However, not necessarily all the genetic
alterations identified by high-throughput sequencing approaches are
driver mutations, and clearly new approaches are needed to better
understand the biologic relevance of these mutations and, hence, their
contributions to the molecular pathways involved inHNSCC initiation
and progression.
By combining our engineered animal models of HNSCC to a rele-
vant chemical carcinogenesis approach using 4-nitroquinoline 1-oxide
(4NQO), we have now developed an oral specific HNSCC animal
model that allowed us to study the different molecular, biologic, and
clinical aspects of HNSCC. This novel animal model closely recapitu-
lates human HNSCC progression and, hence, enabled us to analyze the
contribution of the activation of PI3K/AKT/mTOR pathway and
PTEN deregulation/deactivation and mutations to the development
of HNSCC. We started by deleting Pten selectively from the prolif-
erative epithelial layer using the Cre system driven by the cytokeratin
14 promoter (K14Cre). PTEN is a phosphatase that hydrolyzes phos-
phatidylinositol 3,4,5-trisphosphate (PIP3) to phosphatidylinositol
4,5-bisphosphate (PIP2), hence representing a key negative regulator
of the PI3K/AKT/mTOR pathway [11,12]. Thus, deactivation and/
or down-regulation of PTEN due to mutations, epigenetic changes,
or posttranslational regulation can be recapitulated by the partial
(heterozygous) or complete (homozygous) deletion of the Pten gene,
which results in the activation of PI3K pathway. These mice were
also exposed to a tobacco surrogate, 4NQO, which leads to the
development of oral lesions and malignant transformation within
the oral cavity, similar to that observed in humans. Our animal model
closely mimics the human disease and can be effectively used for
future preclinical studies. Overall, our study shows the importance of
the PI3K/AKT/mTOR and PTEN to HNSCC initiation and progres-
sion and, thus, supports a critical role of this pathway in a subset of
HNSCC patients.
Materials and Methods
Genetically Defined HNSCC Animal Model
All animal studies were carried out according to an institutionally
approved protocol, in compliance with the Guide for the Care and Use
of Laboratory Animals. K14Cre PtenF/F mice were obtained by crossing
as previously described [13,14] to generate K14Cre PtenF/+ (hetero-
zygous deletion), K14Cre PtenF/F (homozygous deletion), and control
mice in the same litter. The mice had free access to water and pellet
stock diet, with the addition of high-fat supplement, when needed.
Genotyping was performed from tail biopsies using a polymerase chain
reaction assay as previously described [13]. 4NQO (Sigma-Aldrich,
St Louis, MO) was diluted in initially dissolved propylene glycol
(4 mg/ml). Sixty 5-week-old littermates were divided into groups of
10 animals and exposed to vehicle or 4NQO (50 μg/ml) in drinking
water for 13 weeks. As previously described, water was changed weekly
allowing minimal intervention [15]. The animals were killed at the end
of the study for final examination and tissue collection. For gene excision
analysis, reportermice was obtained by crossingK14Cre transgenicmice
to ROSA26 (R26R) mice [16] containing a LacZ gene flanked by loxP
sites (ROSA-floxed-lacZ mice).
Histology and Immunohistochemistry of Tissue Microarrays
and Tissue Sections
Hematoxylin and eosin (H&E) staining was performed on formalin-
fixed and paraffin-embedded 4-μm serial sections according to standard
procedures. Immunohistochemistry was performed on these paraffin-
embedded tissue sections as described previously [13,17]. Two distinct
sets of tissue microarrays (TMAs) containing 711 HNSCC (cores) of
normal adjacent oral epithelium, oral dysplasia, and HNSCC were
obtained from the National Institute of Dental and Craniofacial
Research (NIDCR), National Institutes of Health (Bethesda, MD;
n = 347) [18] and from the University of Chicago (n = 362 HNSCC
and 102 normal/dysplasias). For immunohistochemical reaction,
antibodies against PTEN (Cascade Bioscience, Winchester, MA),
pAKTSer473, pAKTThr308, pS6, epidermal growth factor receptor
(EGFR; Dako, Carpinteria, CA), pEGFRTyr1068, and p53 (Cell
Signaling Technology, Danvers, MA) were used. According to the
immunoreactivity, the tissue array sample cores were classified into
five groups: 0 (less than 10% stained cells), 1 (from 10% to 25% of
stained cells), 2 (from 25% to 50% of stained cells), 3 (from 50% to
75% of stained cells), and 4 (from 75% to 100% of stained cells.
PTEN expression was also classified as negative (group 0 or less than
10% stained cells) and positive (groups 1–4 or 10% to 100% of
stained cells). Immunostainings and H&E stains were assessed by
two experienced pathologists. Animals from both cohorts (4NQO
and vehicle) were analyzed, and detailed histopathologic analyses
were performed in each animal at the end of the study. Lesions were
classified as normal, hyperplasias, dysplasias (premalignant lesions),
and carcinomas (all malignant tumors, including carcinomas in situ).
Images were taken using the ScanScope CS System (Aperio Tech-
nologies, Inc, Vista, CA) and QImaging EXi Aqua monochrome
digital camera and Nikon Eclipse 80i Microscope (Nikon, Melville,
NY). Hierarchical clustering analysis were done using the Cluster
program with average linkage based on unsupervised clustering anal-
ysis as the selection variable and visualized using the TreeView pro-
gram. The biomarkers with a close relationship are located next to
each other.
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Cancer Microarray Database and Data Mining Platform
Oncomine (Compendia Bioscience, Ann Arbor, MI) [19] was used
for retrieving the public cancer database information for the analysis of
cancer genes and HNSCC. By the use of the Oncomine data analysis
package, the relationship between alterations in PTEN mRNA expres-
sion levels and lymph node involvement (N0, no lymph node invasion,
and N1+, lymph node invasion in one or more lymph nodes) were
retrieved from the head and neck study of Ginos et al. [20], and the
results were also confirmed with data from head and neck studies of
Cromer et al., Chung et al., and O’Donnell et al. [21–23].
β-Galactosidase Assay
Frozen sample sections (5–6 μm) were fixed with 0.2% glutaral-
dehyde for 2 minutes and washed multiple times in 1× phosphate-
buffered saline. Cryosections were stained with X-Gal solution (2 mg/
ml X-Gal). Staining was performed in the dark at 37°C for 6 to
8 hours, mounted in 80% glycerol, and visualized by differential inter-
ference contrast microscopy, also known as Nomarski Interference
Contrast, using a Zeiss Axiophot microscope [24].
Primary Culture of Keratinocytes and Immunoblot
Murine keratinocytes were isolated and grown in KBM-2 medium
(Cambrex, East Rutherford, NJ) as previously described [14]. After
lyses, protein concentrations were determined and 30 μg of proteins
was separated on 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, transferred to nitrocellulose membranes, blocked with
5% milk protein, and incubated with primary antibodies anti-PTEN
(Cascade Bioscience) and tubulin (Santa Cruz Biotechnology, Dallas,
TX) as previously described [13].
Immunofluorescence and Immunohistochemistry
in Mouse Tissues
Immunofluorescence was performed on 5-μm-thick tissue sec-
tions. The standard procedure was used to dewax and hydrate the
tissues through graded alcohol followed by antigen retrieval and
endogenous peroxidase block. Antibody against pS6 (Cell Signaling
Technology) was incubated at 4°C and overnight in 3%BSA. Fluorescein
isothiocyanate–conjugated secondary antibody ( Jackson Immuno-
Research Laboratories, West Grove, PA) was added as described pre-
viously [14]. Microvessel density was determined following identification
of blood vessels with a polyclonal anti-human factor VIII antibody
(Lab Vision, Fremont, CA). For nuclear staining, Hoeschst 33342 or
mountingmediumwith 4′,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, CA) was used. Antibodies used for immuno-
histochemistry performed in mouse tissue were anti–COX-2 (BD
Transduction Laboratories, San Jose, CA) and pAKT (Cell Signaling
Technology). Images were taken using Zeiss Axio Imager Z1 micro-
scope equipped with an Apotome device (Carl Zeiss, Thornwood,
NY) and ScanScope (Aperio Technologies, Inc).
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 5.00
(GraphPad Software, San Diego, CA). The analysis of variance fol-
lowed by Bonferroni multiple comparison test and Student’s t test
was used. Dunn multiple comparison test was used for lesion size.
Significant differences between two groups were noted by asterisks or
actual P values [*P ≤ .05, **P ≤ .01, ***P ≤ .001, and NS (P > .05,
not significant)].
Results
PTEN Down-Modulation Is Associated with Tumor
Progression and Aggressive Behavior in HNSCC Patients
We started by defining the levels of PTEN expression in normal
epithelium of the oral cavity. Most of the human non-neoplastic tissues
adjacent to tumors (adjacent normal epithelium) expressed moderate
amounts of the tumor suppressor PTEN (Figure 1A). PTEN expression
was observed primarily localized to the proliferative basal layer of the
epithelium (data not shown). These observations are align with our
previous report in which epithelium adjacent to the tumor displayed
up-regulation of PTEN [18], suggesting that these cells increase the
expression of the tumor suppressor PTEN as an early protective re-
sponse during transformation. However, many dysplasias (Figure 1A)
and HNSCC invading tumor cells displayed PTEN down-regulation
(Figure 1A, dysplasia, and insert, WD_HNSCC), which are specially
observed in the areas of epithelial invasion into the surrounding stroma,
indicating that PTEN may be regulated by the interaction of the can-
cer cells with the tumor microenvironment. Indeed, although some
HNSCCs have elevated expression of PTEN (Figure 1A,WD_HNSCC),
the carcinoma invasive front displays down-regulation of PTEN (as
previously reported by us in [14]). We also observed that among the
cases studied, a selected group of HNSCC patients displayed PTEN
down-modulation throughout the tumor lesion (Figure 1, A–C ).
We also took advantage of available databases to analyze whether
PTEN expression in primary tumors inversely correlates with lymph
node spread. Indeed, the involvement of lymph nodes in HNSCC
patients is associated with reduced expression of PTEN (Figure 1D;
***P≤ .001). This suggests that PTEN down-regulation may have prog-
nostic significance, as lymph node invasion correlates with low disease-
free survival and poor overall prognosis of HNSCC patients [25].
PTEN Down-Regulation Is Present in 30% of HNSCCs
and Correlates with the Activation of PI3K/AKT/mTOR
Pathway in HNSCC Patients
We next analyzed multiple HNSCC lesions (NIDCR, n = 347 cores;
University of Chicago, n = 362 cores) among four TMAs by immuno-
histochemistry (IHC) using anti-PTEN antibody. First, all normal oral
epithelia (100%, n = 10) were positive for PTEN, which showed at
least 80% of the cells staining positively within the epithelial basal layer
(Figure 1B). In this large number of HNSCC cases, however, we estab-
lished that 31.2% of HNSCCs displayed down-modulation of PTEN
protein levels (Figure 1B, n = 709, **P < .01 vs normal controls), as seen
in representative examples of positive and negative PTEN stainings in
the selected TMA cores of HNSCC (Figure 1C). Detailed analysis of
the HNSCC TMAs showed distinct immunoreactivity for PTEN,
according to the scoring of positive cells that range from score 0
(10% positive cells) to 4 (100% positive cells; Figure 2A). Interestingly,
lower average PTEN scores were closely related with poorly differenti-
ated HNSCC cases (1.30 ± 0.17), but no differences were observed in
the average staining score for well-differentiated (2.17 ± 0.14) and mid-
differentiated (2.18 ± 0.15) carcinomas (Figure 2B). Next, we evaluated
the relationship between expression levels of PTEN and the status of a
number of key molecules of the PI3K/AKT/mTOR pathway and
important markers associated with HNSCC prognosis and treatment,
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including p53, EGFR, and its phosphorylated active form (pEGFR).
The multiple TMAs allowed us to survey hundreds of tumor tissues
for all the selected markers simultaneously. The results were analyzed
by unsupervised hierarchical clusters based on the similarities of the
seven biomarkers. The cluster analysis was done only in samples that
had staining of at least four of the seven markers used. Approximately
310 data points (HNSCC samples) were included in the analysis and
plotted in a heat map (Figure 2C ). Tissue scores were represented as
follows: 0, green; 1, black; 2, dark red; 3, medium red; 4, bright red.
No available data were represented as gray. The heat map displayed
the expression of proteins and phosphoproteins (Figure 2C , right) in
relation to HNSCC (Figure 2C , top). As expected, pAKTSer473, pS6,
pAKTThr308, and PTEN clustered together, and interestingly, EGFR
was part of this cluster division. However, p53 and pEGFR were clus-
tered separately from these markers. Of note, some tissue clusters be-
came evident. The cluster depicted as A in Figure 2C showed samples
negative for both PTEN and pEGFR, while the cluster represented as
A1 included tumors positive for PTEN and pEGFR simultaneously.
A Genetically Defined Oral HNSCC Animal Model Was
Generated by Combining Intraoral Excision of the Tumor
Suppressor Pten and Local Administration of the Tobacco
Surrogate 4NQO, Which Resulted to HNSCC Tumor
Formation in the Oral Cavity
Pten was conditioned deleted from the epithelial compartment by
crossing mice harboring a floxed Pten allele (PtenF/F) with mice
expressing the Cre recombinase under the control of the K14 promoter
(K14Cre). Effective gene excision in epithelial cells of the tongue
and oral mucosa was confirmed by K14Cre/ROSA-floxed-lacZ mice,
which displayed positivity for β-galactosidase seen in blue (Figure 3A).
Next, as seen in Figure 3B, mice harboring Pten deletion (K14Cre
PtenF/+ and K14Cre PtenF/F) and control mice were exposed to vehicle
Figure 1. Loss of PTEN during tumor transformation and lymph node involvement. (A) Representative examples of PTEN expression in
normal, dysplastic, and HNSCC from humans demonstrating PTEN expression. Note PTEN down-regulation in the dysplastic epithelium
and in the HNSCC epithelial cell invasion (black arrows). (B) Analysis of PTEN expression on oral epithelia (n = 10) and four TMAs for
HNSCC (containing n = 709). In normal oral epithelia, PTEN staining was positive mostly in the basal layer. Note an overall PTEN loss in
31.2% of all HNSCC tumors (**P < .01). (C) Representative examples of PTEN staining in HNSCC TMA tumor core (n = 709; positive,
top; negative, bottom). (D) Scatter plot of relative microarray signal intensities for PTEN mRNA in HNSCC samples from patients with
negative lymph nodes (N0) versus presence of lymph node metastases (N1+; error bar, SEM; **P ≤ .01; ***P ≤ .001).
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or 4NQO, a tobacco surrogate that forms DNA adducts, substitutions
in adenosine for guanosine, oxidative stress, DNA breaks, and muta-
tions, typical from those provoked by tobacco carcinogen [26–28].
Treatment started after weaning and continues for 13 weeks. At the
end of the study, mice were euthanized and tissue was collected. As
expected, none of the control and K14Cre PtenF/+mouse groups treated
with the vehicle in the drinking water developed lesions at the end of the
study (Figure 3C , control). Gross examination of K14Cre PtenF/F mice
from the vehicle-treated group displayed multiple lesions (Figures 3, D
and E , and 4A, K14Cre PtenF/F/vehicle), which were small white
patches clinically similar to leukoplakias. Notably, leukoplakias are
white lesions that have been associated with a higher risk of transforma-
tion, mostly present in adults more than 40 years of age, and cancer pre-
valence increases rapidly with age [29,30]. These observations may
indicate that PTEN down-modulation predisposes the oral epithelium
to transformation. Here, we chose to work with BALB/c mice, a strain
shown to be resistant to the carcinogenic effects of 4NQO [26], hence
providing amore sensitive biologic system to explore the contribution of
Pten. Indeed, control mice did not develop lesions throughout the study
(Figure 3C , control). However, our model combining Pten deletion
with 4NQO treatment allowed us to determine specific contribution
of PTEN down-modulation and subsequent PI3K/mTOR activation
to HNSCC. Remarkably, K14Cre PtenF/+ and K14Cre PtenF/F mice
developed lesions as early as in 6 weeks of 4NQO exposure. Most of
the lesions developed as irregular growth ranging fromwhite appearance
to ulcerated lesions on the lateral border and ventral part of the tongue
and floor of themouth (Figure 3,C andD), which are some of themost
common sites of intraoral carcinomas in humans. Of note, K14Cre
PtenF/F mice exposed to 4NQO also displayed widespread dysplastic
white lesions on the dorsal, ventral, and lateral borders of the tongue
(Figure 3, C and D), which resemble the “field cancerization” that is
often associated with tobacco exposure and higher risk of developing
multiple carcinomas in humans [2,4,31,32].
The Pten/4NQO Animal Model Recapitulates
HNSCC Development and Progression and
Displays PI3K/mTOR Activation
The number and size of the intraoral tumors from mice displaying
Pten down-modulation continued to grow progressively even after the
removal of 4NQO from the drinking water (Figure 3, E and F). Over-
all, these mice developed one or more large intraoral tongue lesions
(Figure 3F ; P ≤ .001). Indeed, clinical visible lesions of the tongue
Figure 2. Evaluation for PTEN and proteins in the PI3K/mTOR pathways in HNSCC samples. (A) HNSCC TMA slides (NIDCR) were
analyzed for PTEN (IHC). PTEN immunoreactivity in the tissue array cores (n= 347) was classified into five groups: 0 (less than 10% stained
cells), 1 (10–25%), 2 (25–50%), 3 (50–75%), and 4 (75–100%). (B) PTEN levels in well-differentiated (wd), moderately differentiated (md),
and poorly differentiated (pd) tumors. Scores were represented as average of PTEN stain per differentiation group (error bar, SEM; ***P ≤
.001). Poorly differentiated tumors (pd) express significantly lower levels of PTEN than well-differentiated (wd) or moderately differenti-
ated carcinomas (md). (C) Heat map generated from the IHC analysis of the indicated proteins in the tissue microarray. Unsupervised
clustering analysis shows correlation between pAKTSer473, pS6, EGFR, pAKTThr308, and PTEN. Separation of clusters was indicated for
the groups inwhich PTEN and pEGFR are co-expressed (A), whereas cluster A1 defines a subgroup of HNSCC lesions inwhich both proteins
are decreased.
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Figure 3. Loss of Pten combined with 4NQO exposure promotes oral tumor formation. (A) Detection of gene deletion in blue (β-galactosidase
activity assay) driven by the K14Cre promoter is seen in the epithelial cells from mouse oral mucosa and tongue. (B) The immunoblot shows
reduced or absent levels of Pten in epithelial cells in primary keratinocyte cultures isolated from K14Cre PtenF/+ and K14Cre PtenF/F mice.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. Control, K14Cre PtenF/+, and K14Cre PtenF/F mouse
groups (n = 10 per group) started treatment with vehicle or 4NQO in drinking water after weaning (∼5-week-old mice). Mice were killed on
week18. (C) The tongueof eachmousewasexaminedgrossly andhistologically as described inMaterials andMethods section.Representative
photographs of lesion on the dorsum, lateral border, and ventral part of the tongue are seen for each 4NQO treatment group and control. No
gross changes were observed in untreated control mice. Elevated white lesions and tumor masses, often ulcerated, were found in K14Cre
PtenF/+ and K14Cre PtenF/F mice treated with 4NQO. (D) The average lesion size experimental group (control, K14Cre PtenF/+, and K14Cre
PtenF/F) is depicted according to their anatomic location in the tongue, ventral/floor, and lateral border, for vehicle and 4NQO treatments.
(E) The average size in mm2 of lesions per mouse is shown for each experimental group. Dots represent the sum of all lesions in each mouse
tongue. (F) Tumor multiplicity is shown as the average of number of lesions per experimental group treated with vehicle and 4NQO (error bar,
SEM; *P ≤ .05, **P ≤ .01, ***P ≤ .001, and NS, not significant).
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in K14Cre PtenF/+ and K14Cre PtenF/F animals had an average size of
10.4 ± 5.1 and 12.0 ± 3.6 mm2, respectively (Figure 3E). As expected,
control and K14Cre PtenF/+ mice treated with the vehicle did not
develop lesions at the end of the study. Of interest, 50% of the mice
with deletion of both alleles of Pten, K14Cre PtenF/F, displayed mul-
tiple small leukoplakias throughout the oral mucosa and tongue, which
together affected an average of 4.6 ± 1.5 mm2 per mouse (Figure 3E ,
vehicle). Histologically, control animals displayed a normal keratinized
stratified squamous epithelium forming the tongue papillae (Figure 4,
A and C , vehicle/control). Half of K14Cre PtenF/+ mice displayed
epithelial changes (hyperplasia) such as a discrete increase in keratin
expression and in the thickness of the epithelial layers (Figure 4, A
and C , vehicle/K14Cre PtenF/+). K14Cre PtenF/F mice displayed
multiple hyperplastic and dysplastic lesions. Histologic analysis dis-
played hyperchromatic (darkening of) nuclei, enlargement of the
epithelial layers including the spinous layer (acanthosis), premature
keratinization of cells (dyskeratosis), loss of progressive maturation
or epithelial layer toward the surface (loss of epithelium polarity),
and an enlarged keratin surface (hyperkeratosis), which are aligned
with the clinical observations of leukoplakias in these mice (Fig-
ure 4, A and C , vehicle/K14Cre PtenF/F). Although clinical changes
on the surface of the tongue could not be observed in the control
mice under 4NQO treatment, most likely because the keratin
thickness was not changed, histologically 20% of the mice displayed
hyperplasia-associated changes in the epithelial maturation and
increased thickness of the spinous and granulous layers (acanthosis;
Figure 4, B and C , 4NQO/control). At the end of the treatment,
all K14Cre PtenF/+ and K14Cre PtenF/F mice displayed abnormal
epithelial changes that ranged from hyperplasia to carcinomas (Fig-
ure 4, B and C ). All malignant tumors were identified with dif-
ferent degrees of keratinization and angiogenesis. Multiple
malignant epithelial cells formed invasive masses of islands and
cords. A small percentage of K14Cre PtenF/+ mice presented only
hyperplasias (20%) or potential precancerous lesions (dysplasias;
20%). Approximately 60% of these mice exhibited invasive and ag-
gressive squamous cell carcinomas. However, all K14Cre PtenF/F
mice exposed to 4NQO displayed multiple or extensive dysplasias,
and 100% of these mice presented with squamous cell carcinomas,
which ranged from in situ to superficially and deeply invasive carci-
nomas (Figure 4C ).
Because PI3K/mTOR signaling is frequently upregulated in patients
with HNSCC, we next investigated the activation status of this path-
way in our HNSCC carcinogenesis model in hyperplastic, dysplastic,
and tumor lesions. Lesions were stained for pS6, a well-defined bio-
marker used in preclinical and clinical studies to establish mTOR acti-
vation [33]. Initially, we found few positive cells close to the surface of
the tongue epithelium of control mice (Figure 4A, control/vehicle and
4NQO). The positive cells were in the granular layer, a nonproliferative
and more differentiated keratinocyte compartment. mTOR activation,
as judged as pS6 accumulation, increased upon 4NQO treatment,
which expanded along the hyperplastic lesions. Interesting, a progres-
sive dysregulation of PI3K/mTOR pathway was observed. Hyperplastic
and dysplastic lesions of K14Cre PtenF/+ and K14Cre PtenF/F mice also
displayedmTOR activation, which were further accentuated by 4NQO
treatment (Figure 4,A andB). The increased expression of pS6 gradually
expanded toward the spinous, suprabasal, and basal layers, which were
absent in control animals (Figure 4B). Furthermore, tumors in our ani-
mal model presenting Pten deletion showed multifocal areas of mTOR
activation throughout the tumor (Figure 4B, tumors).
Pten Down-Regulation Leads to Augmented Angiogenesis
and Increased COX-2 Expression and Does Not Require
the Expression of Mutant p53
In addition to the direct impact of Pten down-regulation on the
squamous epithelial cells, we next explored whether decreased Pten
expression could alter the microenvironment in which the SCC tumors
arise. We studied the effects of Pten deregulation in angiogenesis by
analyzing the number of blood vessels present in the tongue of mice
with Pten deregulation. As seen in Figure 5A, the density of blood ves-
sels increased following Pten deletion, indicating that Pten deregula-
tion in epithelial cells can promote a cross talk between epithelial and
stromal cells to create a specific niche more susceptible to tumor for-
mation. COX-2 has been shown to be unregulated in HNSCC and to
participate in tumor angiogenesis and tumor progression [34–36].
Here, we found that in control animal exposed to 4NQO, COX-2
expression was found confined to the connective tissue. However,
COX-2 expression was found in dysplastic epithelial cells as well in oral
tumors upon Pten down-modulation. Indeed, Pten deletion was suffi-
cient to cause increased angiogenesis in the surrounding stroma, and
tumors arising in conditional Pten mice exhibited increased levels of
the proinflammatory molecule COX-2, even in dysplastic lesions.
Thus, decreased PTEN levels in tumor tissues may initiate an angio-
genic and proinflammatory process in the surrounding oral mucosa.
Next, we analyzed p53 expression. p53 was found not to be expressed
in Pten-dependent dysplasias and oral tumors, suggesting that PTEN
down-regulation may circumvent the requirement of p53 mutations.
This is aligned with the fact that many human tumors displaying re-
duced PTEN levels do not exhibit accumulation of p53, often reflect-
ing the presence of mutations in its encoding gene. As expected, we also
observed increased phosphorylation of AKT, using pAKTSer473 as read-
out, in dysplastic and tumor lesions in mice in which the Pten gene was
conditionally deleted, aligned with the increased activation of this sig-
naling molecule and the mTOR pathway in human HNSCC tissues.
Altogether, these findings provide a strong rationale for further clinical
and preclinical studies with mTOR inhibitors to prevent and treat
HNSCC. Furthermore, because a subset of patients may present higher
PI3K/mTOR activation as a consequence of PTEN mutations and
inactivation, PI3K and TSC1/2 mutations, these patients could poten-
tially benefit the most from this targeted therapy.
Discussion
In this study, we investigated the potential ability of combining two
major players in HNSCC formation to engineer an animal model for
intraoral HNSCC capable of recapitulating the fundamental genetic
and biologic characteristics of HNSCC tumors. Specifically, the car-
cinogenic potential of tobacco was studied here by the administration
of its chemical surrogate, 4NQO, and associated with the selective
up-regulation of a growth-promoting pathway represented by PI3K/
mTOR. Most HNSCC patients present key genetic and epigenetic
alterations that lead to aberrant gene and protein expression. Along
mutations in the p53 and Notch genes, activating mutations in the
PIK3CA gene, often referred to as the PIK3CA oncogene, results in
constitutive activation of AKT and downstream proteins such as mTOR
[5,6,37,38]. Furthermore, AKT is known to be activated in the majority
of HNSCC tumor tissue and cell lines [18,39], and its active form is
detected in 50% of preneoplastic lesions [40]. The activation of this
pathway is caused by multiple genetic and epigenetic events in HNSCC,
including mutations in the RAS and PIK3KCA oncogenes, as well as by
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Figure 5. Pten deletion induces angiogenesis and up-regulation of pAKT activity and COX-2 expression in epithelial dysplasias and oral tumors.
(A) Blood vessel density was detected by factor VIII staining and defined as number of blood vessels per field. Micrographs are representa-
tive examples of blood vessels stainedwith factor VIII (arrow) in oral tissue fromcontrol, K14Cre PtenF/+, andK14Cre PtenF/Fmice (***P< .001).
(B) Oral dysplasias and tumors induced by the tobacco surrogate (4NQO) with Pten deregulation (K14Cre PtenF/F) display up-regulation of
pAKTSer473 and COX-2, the latter in both the epithelial cells and the tumor stroma, and do not involve the accumulation of mutant p53.
Figure 4. Gradual loss of Pten leads to increased number of carcinomas in the oral cavity after exposure to 4NQO. The tongue of every
mouse from control, K14Cre PtenF/+, and K14Cre PtenF/F groups (n= 10 per group) was processed for histologic examination as described
in Materials and Methods section. Representative histologic pictures (H&E stain) of each group of mice treated with vehicle (A) and 4NQO
(B) are depicted. (A) Representative example of tongue histologic section from control mice (vehicle treated) displaying normal histologic
features. Hyperplasia and dyskeratosis are common features of K14Cre PtenF/+. K14Cre PtenF/F dysplastic changes such as hyperchromatic
nuclei, acanthosis, dyskeratosis, loss of epithelium polarity, and hyperkeratosis (see text for details) were also seen. Positive immuno-
reactivity of the mTOR downstream target pS6 in normal tissues is limited to the upper layers of the squamous epithelium of the dorsal
tongue (control/vehicle). Increased expression of pS6 is found on K14Cre PtenF/+ and K14Cre PtenF/F mouse tissues. Most keratinocytes
from K14Cre PtenF/F mice displayed pS6 expression regardless of their differentiation stage. (B) Exposure to the carcinogen (4NQO) induced
moderate histologic changes in control mice (hyperplasia and dyskeratosis). K14Cre PtenF/+ and K14Cre PtenF/F developed carcinomas in
the tongue. Dysregulated activation of mTOR (shown by pS6 expression) is found in all mouse groups treated with 4NQO. pS6 immuno-
reactivity is further increased by the Pten ablation (as seen in K14Cre PtenF/+ and K14Cre PtenF/F). The lower photographs show high
up-regulation of mTOR activity (pS6 expression) in tumors with Pten ablation (left, K14Cre PtenF/+; right, K14Cre PtenF/F). (C) Normal,
hyperplasia, dysplasias (preneoplastic lesions), and carcinomas were evaluated in histologic slides from the tongue of each animal. The
results are expressed as percentage of the total changes in each experimental group.
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EGFR overexpression and by the expression of constitutively activated
truncated mutant forms of EGFR, EGFRvIII [41].
In general, the molecular events responsible for AKT/mTOR ac-
tivation involves PI3K activation, which promotes PIP3 synthesis by
phosphorylating PIP2 in the 3 position of the inositol ring at the cell
membrane, which in turn promotes AKT phosphorylation. PTEN is
a lipid phosphatase that directly opposes PI3K by dephosphorylat-
ing PIP3 and thus inhibits its downstream signaling [11,12,42,43].
Therefore, PTEN is responsible for blocking the PI3K pathway, and
PTEN inactivation or deletion mimics activating PI3K/AKT/mTOR
pathway mutations and epigenetic alterations [44]. Moreover, under-
scoring PTEN contribution to HNSCC, PTEN gene has been shown
to be mutated in 8% to 23% of HNSCCs [6–8], and as shown here,
PTEN protein is absent or downregulated in approximately 30% of
HNSCC cases. Furthermore, the lack of PTEN expression often results
in aggressive tumors, which is reflected by PTEN association to poor
disease-free and overall survival [44].
In vivo studies of important genes involved in HNSCC are mostly
accomplished using transgenic animal models engineered to target
the expression of a variety of oncogenes in the epidermis, which
result in the development of papillomas and carcinomas in the skin
[45–48]. Some animal models also rely in the addition of 7,12-
dimethylbenz[α]anthracene (DMBA)/12-O-tetradecanoyl-phorbol-
13-acetate (TPA), which involves the activation of RAS, an important
component often found in a subset of tumors in Asia associated with
the use of areca nut [49]. These multistage animal models result in the
formation of papillomas that further progress to full-blown carcinomas
in a process rarely observed in Western HNSCC [50–52]. Here, we
combined the intraoral administration of a tobacco surrogate, 4NQO,
with the conditional deletion of the Pten gene using Pten floxed mice.
This resulted in overactivity of PI3K/AKT/mTOR caused by Pten
ablation from the proliferative layer of the oral mucosa using the
CRE-lox systemunder the keratin promoter 14. This provided a specific
genetic and environmentally defined animal model for HNSCC that
resulted in the development of oral specific carcinomas. Remarkably,
most of the tumors arose in the lateral border and ventral part of the
tongue and floor of the mouth, which are preferred anatomic sites for
human HNSCC. Furthermore, the presence of malignant carcinomas
in the animal cohort bearing both deficiency for Pten and 4NQO
administration argues that combined factors, such as epigenetic events
resulting in reduced PTEN levels or genetic alterations in its coding
gene, together with tobacco exposure, can cause tumors to arise and
to progress to a fully malignant state, often in a multifocal fashion.
Overall, our study highlights the likely clinical relevance of reduced
PTEN expression and/or inactivation in HNSCC progression. In
addition, the intraoral tumors arising in our genetically definedHNSCC
animal model closely mimic the histology and etiology of human
HNSCC often found in tobacco users, presenting similar progression
pattern and activated pathways. Thus, the combined Pten deletion with
exposure to tobacco carcinogens or their surrogates may provide a
unique model system to study novel molecular target treatments for
HNSCC patients.
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